Cefiderocol
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis, Pneumonia, Bacterial
Trial Timeline
Jun 1, 2022 → Dec 11, 2024
NCT ID
NCT05314764About Cefiderocol
Cefiderocol is a approved stage product being developed by Shionogi for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05314764. Target conditions include Cystic Fibrosis, Pneumonia, Bacterial.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03780140 | Pre-clinical | Completed |
| NCT07465432 | Approved | Recruiting |
| NCT05789199 | Pre-clinical | Completed |
| NCT05373615 | Phase 1 | Completed |
| NCT05314764 | Approved | Completed |
| NCT04995835 | Phase 1 | Completed |
| NCT03869437 | Phase 2 | Completed |
Competing Products
20 competing products in Cystic Fibrosis